Recent randomized trials showed that, programmed death-ligand 1 (PD-L1) and programmed death-1 (PD-1) antibodies, two kinds of checkpoint inhibitors which promote anticancer immunity by blocking PD-1 and PD-L1 interaction and reactivate suppressed immune cells, significantly extended survival over chemotherapy in second- and third-line therapy in advanced NSCLC patients, including the WT EGFR patients [24-27]. Here, CD274 is linked to non-small cell lung carcinoma.